Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized, double-blind trial of bermekimab versus placebo and dupilumab in moderate to severe atopic dermatitis
jRCT2011210006Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in atopic dermatitis (AD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: EASI-75 at Week 16 for bermekimab efficacy. Started Jun 2021; status: completed.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2011210006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210006.